Biosimilars 2020 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
FEBRUARY 4, 2021
The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. Note that FDA still has not designated any biosimilar as interchangeable to its reference product. No earlier than July 31, 2023 per settlement. No earlier than November 20, 2023 per settlement. . Introduction.
52 
Let's personalize your content